±¾´Î´ó»á·¢±íµÄÊ¥ÂÞÀ³?Ñо¿³É¹ûÀ´×ÔÈ«¹úÊ®¶à¸ö²»Í¬Ê¡ÊеÄÒ½Ôº£¬ÄÚÈݰüº¬ÅàĪɳëĵÄÕæÊµÊÀ½çÑо¿¡¢²¡Àý±¨¸æºÍ»úÖÆÑо¿µÈ£¬²»½öÆÀ¹ÀÁËÅàĪɳëÄÔÚ͸Îö/·Ç͸ÎöÂýÐÔÉöÔಡ£¨CKD£©Æ¶Ñª»¼ÕßÖеÄÁÆÐ§ºÍ°²È«ÐÔ£¬»¹Ì½Ë÷ÁËÅàĪɳëÄÔÚÉöÒÆÖ²¡¢´¿ºìϸ°ûÔÙÉúÕϰÐÔÆ¶Ñª£¨PRCA£©¡¢ºìϸ°ûÉú³É´Ì¼¤¼Á£¨ESA£©µÍ·´Ó¦ÒÔ¼°ÄÑÖÎÐÔÉöÐÔÆ¶ÑªµÈ¸ü¶àϸ·ÖÈËȺÖеÄÓ¦Ó㬴ӶøÎªÉöÐÔÆ¶ÑªÁÙ´²Êµ¼ùÖÐÃæÁÙµÄÖî¶àÒÉÄÑÌôÕ½ÌṩеĽâ¾ö·½°¸¡£
ÒÔÏÂÊDZ¾´Î»áÒéÊÕ¼µÄÅàĪɳëÄÏà¹Ø±Ú±¨¼°ÂÛÎÄ[1]¡£
1.´Ùºìϸ°ûÉú³ÉËØÄ£ÄâëÄÅàĪɳëÄÖÎÁÆ·Ç͸ÎöÒÀÀµÐÍ 1 ÐÍÌÇÄò²¡Éö²¡»¼Õß´¿ºìϸ°ûÔÙÉúÕϰÐÔÆ¶Ñª
×÷ÕߣºÉϺ£ÊеÚÒ»ÈËÃñÒ½Ôº ·¶ÇïÁ飬µÈ
2.ÅàĪɳëÄ×¢ÉäÒºÔÚ³õʼ¸¹Ä¤Í¸Îö»¼ÕßÖÐÓÐЧÐÔÓ밲ȫÐÔµÄÕæÊµÊÀ½çÑо¿
×÷ÕߣººÓÄϿƼ¼´óѧµÚÒ»¸½ÊôÒ½Ôº ³£½à£¬µÈ
3.ÅàĪɳëijɹ¦ÖÎÁÆEPOÓÕµ¼µÄ´¿ºìϸ°ûÔÙÉúÕϰÐÔÆ¶£¨PRCA)1Àý
×÷ÕߣºÄϲý´óѧµÚÒ»¸½ÊôÒ½Ôº Û³ÑÞ£¬µÈ
4.ÆÀ¹ÀEMPÔÚѪҺ͸Îö»¼Õ߯¶Ñª¼°ÐÄѪ¹Ü»ñÒæµÄÁÆÐ§Ñо¿
×÷ÕߣºÖØÇìÒ½¿Æ´óѧ¸½Êô´óѧ³ÇÒ½Ôº ÑîÓ°£¬µÈ
1.Efficacy and Safety of Pegmolesatide in Kidney Transplant Recipients with anemia
×÷ÕߣºËÄ´¨´óѧ»ªÎ÷Ò½Ôº ʯÔËÓ¨£¬µÈ
2.EPO-Mimetic Peptide Pegmolesatide Therapy for Pure Red Cell Aplasia in a Patient with Non-dialysis- dependent Type 1 Diabetic Nephropathy: A Case Report
×÷ÕߣºÉϺ£ÊеÚÒ»ÈËÃñÒ½Ôº ·¶ÇïÁ飬µÈ
3.ÅàĪɳëÄͨ¹ýÒÖÖÆEPOR/CD131-JAK2/STAT3ͨ·¸ÄÉÆCKDÏà¹ØÐļ¡Ï¸°û·Ê´ó
×÷Õߣº±±¾©´óѧÈËÃñÒ½Ôº ×óÁ¦£¬µÈ
4.ÅàĪɳëÄÖÎÁÆÂýÐÔÉöÔಡÉöÐÔÆ¶Ñª1ÖÜʱµÄÔçÆÚÁÆÐ§Ó밲ȫÐÔ£ºÒ»Ïî»Ø¹ËÐÔ¶ÓÁÐÑо¿
×÷ÕߣºËÄ´¨´óѧ»ªÎ÷Ò½Ôº ¸¶Æ½£¬µÈ
5.ÅàĪɳëÄ×¢ÉäÒºÖÎÁÆÑªÍ¸»¼ÕßÉöÐÔÆ¶ÑªµÄÓÐЧÐԺͰ²È«ÐÔÑо¿
×÷Õߣº¸´µ©´óѧ¸½ÊôÖÐɽҽԺ ¶¡Ð¡Ç¿£¬µÈ
6.ÅàĪɳëÄÔÚ½ÓÊܹý´Ùºìϸ°ûÉú³ÉËØÖÎÁƵÄ͸ÎöÈËȺÖÐÓÐЧÐԺͰ²È«ÐÔ:Ò»ÏîÕæÊµÊÀ½çÑо¿
×÷ÕߣºÄþ²¨´óѧ¸½ÊôµÚÒ»Ò½Ôº ±ßѧÑ࣬µÈ
7.ÅàĪɳëÄÖÎÁÆ´Ùºìϸ°ûÉú³ÉËØµÍ·´Ó¦Î¬³ÖÐÔѪҺ͸Îö»¼ÕßµÄÁÆÐ§·ÖÎö
×÷Õߣº¸£½¨Ê¡ÄþµÂÊÐÃö¶«Ò½Ôº ÁÖÌÚÇ¿£¬µÈ
8.ÅàĪɳëÄÖÎÁÆÉöÐÔÆ¶ÑªµÄÑÖ¤Ñо¿½øÕ¹
×÷ÕߣºÊ¯¼ÒׯÊеÚÈýÒ½Ôº ²ÜÒ带£¬µÈ
9.ÅàĪɳëÄÖÎÁÆÂýÐÔÉöÔಡ·Ç͸ÎöÉöÐÔÆ¶Ñª»¼ÕßÁÆÐ§¼°°²È«ÐÔÆÀ¹À
×÷ÕߣººÓÄϿƼ¼´óѧµÚÒ»¸½ÊôÒ½Ôº ³£½à£¬µÈ
10.ÅàĪɳëÄÖÎÁÆÄÑÖÎÐÔÉöÐÔÆ¶ÑªµÄÓÐЧÐÔÓ밲ȫÐÔ
×÷ÕߣºÄϾ©Ò½¿Æ´óѧ¸½ÊôÌ©ÖÝÈËÃñÒ½Ôº ²ÜæºæÂ£¬µÈ
11.ÅàĪɳëÄÖÎÁÆÎ¬³ÖÐÔ¸¹Ä¤Í¸Îö»¼ÕßÉöÐÔÆ¶ÑªµÄÁÆÐ§¹Û²ì
×÷ÕߣºÉòÑôÊеÚËÄÈËÃñÒ½Ôº ¹ù࣬µÈ
12.²¡Àý±¨¸æ£ºÅàĪɳëÄÁªºÏÂÞɳ˾ËûÔÚ´¿ºìϸ°ûÔÙÉúÕϰÐÔÆ¶ÑªÖÎÁÆÖеÄÓ¦ÓÃ
×÷Õߣº°²ÄþÊеÚÒ»ÈËÃñÒ½Ôº ÀîÐøÃ·£¬µÈ
×Ô2023Äê6ÔÂÉÏÊÐÒÔÀ´£¬Ê¥ÂÞÀ³?Òѹ㷺ÓÃÓÚCKDÏà¹ØÆ¶ÑªµÄÖÎÁÆ£¬²¢ÏȺó±»ÄÉÈë¡¶³¤Ð§ºìϸ°ûÉú³É´Ì¼¤¼ÁÖÎÁÆÉöÐÔÆ¶ÑªÖйúר¼Ò¹²Ê¶£¨2024Äê°æ£©¡·[2]¡¢¡¶Ö¸µ¼ÉöÐÔÆ¶Ñª»¼Õß×ÔÎÒ¹ÜÀíµÄÖйúר¼Ò¹²Ê¶(2024 °æ)¡·[3]ÒÔ¼°¡¶ÑÓ»ºÂýÐÔÉöÔಡ½øÕ¹ÁÙ´²¹ÜÀíÖ¸ÄÏ£¨2025Äê°æ£©¡·[4]¶à¸öÖ¸ÄϹ²Ê¶ÍƼö¡£
±¾´Î´ó»áÈëÑ¡µÄÉÏÊöÑо¿³É¹û²»½ö·á¸»ÁËÊ¥ÂÞÀ³?µÄÑÖ¤Ö¤¾Ý£¬»¹ÓÐÖúÓÚÍÆ¶¯ÉöÐÔÆ¶ÑªÁìÓòµÄ·¢Õ¹£¬Îª´Ù½ø¹úÄÚCKDƶѪµÄ¹æ·¶»¯ÖÎÁÆ¡¢Ìá¸ßÉöÐÔÆ¶Ñª»¼ÕßµÄÉú´æÔ¤ºó¹±Ï×Á¦Á¿¡£
²Î¿¼ÎÄÏ×£º
1.https://ccsn2025.sciconf.cn/cn/web/abstract-search/31448
2.ÖлªÉöÔಡÔÓÖ¾,2024,40(2):146-157.
3.ÖйúѪҺ¾»»¯,2025,24(1):1-12
4.ÖлªÉöÔಡÔÓÖ¾, 2025, 41(6): 455-488.
¹ØÓÚµÏÍþÖÆµÏÍþ¹ú¼Ê
ÃâÔðÉùÃ÷
ǰհÐÔ˵Ã÷